Beckley Psytech

Transforming psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.

General Information
Company Name
Beckley Psytech
Founded Year
2019
Location (Offices)
Oxford, United Kingdom +1
Founders / Decision Makers
Lady Amanda Feilding - Founder Cosmo Feilding Mellen - Chief Executive Officer & Co - Founder Andy Page - Chief Operating Officer Laura Trespidi - Chief Development Officer
Number of Employees
68
Industries
Biotechnology, Health Care
Funding Stage
Corporate Round
Social Media

Beckley Psytech - Company Profile

Beckley Psytech is a private, clinical-stage biotechnology company established in 2019 with a focus on transforming psychedelics into rapid-acting medicines for neuropsychiatric disorders. Leveraging more than two decades of research from the Beckley Foundation, the company aspires to integrate psychedelic medicines into modern medical practice, specifically targeting patients grappling with depression and other debilitating neuropsychiatric conditions. Their recent $40.00M Corporate Round investment came from ATAI Life Sciences, signifying a crucial milestone in their journey. With headquarters in the United Kingdom, Beckley Psytech aims to alleviate the societal burden of these conditions through innovative neuropsychiatric drug development. This endeavor holds promise for improved patient outcomes and enhanced treatment within the healthcare and biotechnology industries.

Taxonomy: Psychedelic Medicine, Neuropsychiatric Disorders, Drug Development, Clinical-Stage Biotechnology, Therapeutic Potential, Psilocybin, Mental Health Treatment, Beckley Foundation, Pharmaceuticals, Clinical Validation, Mental Health Research, Patient Outcomes, Neuropsychiatric Conditions, Depression Treatment

Funding Rounds & Investors of Beckley Psytech (7)

View All
Funding Stage Amount No. Investors Investors Date
Corporate Round $40.00M 1
ATAI Life Sciences, investor in Beckley Psytech's Corporate Round round
04 Jan 2024
Secondary Market $10.00M 1
ATAI Life Sciences, investor in Beckley Psytech's Secondary Market round
04 Jan 2024
Series B £58.00M 10
FJ Labs, investor in Beckley Psytech's Series B round Catalytic Impact Foundation, investor in Beckley Psytech's Series B round Leafy Tunnel, investor in Beckley Psytech's Series B round Negev Capital, investor in Beckley Psytech's Series B round Prime Movers Lab, investor in Beckley Psytech's Series B round PsyMed Ventures, investor in Beckley Psytech's Series B round Whatif Ventures, investor in Beckley Psytech's Series B round Palo Santo, investor in Beckley Psytech's Series B round Oryx Ventures, investor in Beckley Psytech's Series B round Razor Capital, investor in Beckley Psytech's Series B round
15 Aug 2021
Series B Unknown 2 Bossanova Investimentos, Bicycle Day Ventures 01 May 2021
Venture Round £14.00M 6
Noetic Fund, investor in Beckley Psytech's Venture Round round Redbus Ventures, investor in Beckley Psytech's Venture Round round
Richard Reed, Jim Mellon +2 		23 Dec 2020

View All 7 Funding Rounds

Latest News of Beckley Psytech

View All

No recent news or press coverage available for Beckley Psytech.

Similar Companies to Beckley Psytech

View All
Endosane Pharmaceuticals - Similar company to Beckley Psytech
Endosane Pharmaceuticals Restoring the neurophysiological balance.
Psyomics - Similar company to Beckley Psytech
Psyomics Technology to help people get the mental health support they need sooner.
TripSitter Clinic - Similar company to Beckley Psytech
TripSitter Clinic Transform your life through psychedelic assisted healing.
Diamond Therapeutics - Similar company to Beckley Psytech
Diamond Therapeutics Revolutionizing the treatment of mental health
Psylo - Similar company to Beckley Psytech
Psylo Psychedelic-inspired medicine to treat mental illness